<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Large amounts of brain nitric <z:chebi fb="177" ids="25741,29356">oxide</z:chebi> are produced over several hours after a <z:hpo ids='HP_0001297'>stroke</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>This probably causes DNA strand nicks, nitration of cytosolic components of neurons, and ultimately neuronal <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
<SENT sid="2" pm="."><plain>Oxymatrine and matrine are two major <z:chebi fb="13" ids="22315">alkaloids</z:chebi> of the Chinese herb Sophora flavescens Ait </plain></SENT>
<SENT sid="3" pm="."><plain>(Leguminosae); they have been demonstrated to inhibit liver injury during <z:e sem="disease" ids="C1567664" disease_type="Disease or Syndrome" abbrv="">warm ischemia</z:e> and reperfusion and to induce <z:mpath ids='MPATH_3'>apoptosis</z:mpath>, respectively, in vivo and in vitro </plain></SENT>
<SENT sid="4" pm="."><plain>However, the neuroprotective efficacy of the EtOAc extract of S. flavescens (ESF) without the <z:chebi fb="13" ids="22315">alkaloids</z:chebi> has not been explored </plain></SENT>
<SENT sid="5" pm="."><plain>This study investigated the inhibitory efficacy of ESF, which contain two major <z:chebi fb="5" ids="47916">flavonoids</z:chebi> kurarinone (45.5%) and sophoraflavone G (14.7%), in focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>Focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> was induced using the middle cerebral <z:mp ids='MP_0006134'>artery occlusion</z:mp> (MCAO) method </plain></SENT>
<SENT sid="7" pm="."><plain>After 1.5h of MCAO and 24h of reperfusion, the extent of neurological deficits and the <z:mpath ids='MPATH_124'>infarct</z:mpath> volume were measured in Sprague-Dawley rats </plain></SENT>
<SENT sid="8" pm="."><plain>Compared with <z:chebi fb="0" ids="15727">carnosine</z:chebi> (50mg/kg), as positive control ESF (20mg/kg) significantly reduced <z:mpath ids='MPATH_124'>infarct</z:mpath> volume and neurological deficits </plain></SENT>
<SENT sid="9" pm="."><plain>Treatment of human SH-SY5Y cells with <z:chebi fb="0" ids="29321">sodium nitroprusside</z:chebi> (SNP), a <z:chebi fb="0" ids="50566">nitric oxide donor</z:chebi>, decreased cell viability by causing <z:mpath ids='MPATH_3'>apoptosis</z:mpath>-like cell <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
<SENT sid="10" pm="."><plain>ESF significantly inhibited caspase-3-like enzyme activity and DNA fragmentation </plain></SENT>
<SENT sid="11" pm="."><plain>The level of active caspase-3 was maximal 6h after SNP treatment </plain></SENT>
<SENT sid="12" pm="."><plain>However, active caspase-3 and <z:mpath ids='MPATH_3'>apoptosis</z:mpath> were dose-dependently inhibited by ESF treatment </plain></SENT>
<SENT sid="13" pm="."><plain>Flow cytometry analysis showed that ESF significantly inhibited cell <z:mpath ids='MPATH_3'>apoptosis</z:mpath> (p&lt;0.05) and reduced the apoptotic index by 79.9% (p&lt;0.01) </plain></SENT>
<SENT sid="14" pm="."><plain>These results indicate that ESF is neuroprotective in focal <z:hpo ids='HP_0002637'>cerebral ischemia</z:hpo> and the <z:chebi fb="5" ids="47916">flavonoids</z:chebi> in ESF might be responsible for its neuroprotective activity in rats, alone or in part </plain></SENT>
</text></document>